John G Ullman & Associates Inc. Has $18.51 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

John G Ullman & Associates Inc. boosted its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 360,781 shares of the biopharmaceutical company’s stock after buying an additional 5,652 shares during the quarter. Bristol-Myers Squibb accounts for approximately 2.9% of John G Ullman & Associates Inc.’s investment portfolio, making the stock its 5th largest position. John G Ullman & Associates Inc.’s holdings in Bristol-Myers Squibb were worth $18,512,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Herold Advisors Inc. boosted its position in shares of Bristol-Myers Squibb by 3.2% in the 3rd quarter. Herold Advisors Inc. now owns 33,668 shares of the biopharmaceutical company’s stock valued at $1,954,000 after purchasing an additional 1,051 shares during the period. Kestra Private Wealth Services LLC boosted its position in shares of Bristol-Myers Squibb by 9.5% in the 3rd quarter. Kestra Private Wealth Services LLC now owns 139,811 shares of the biopharmaceutical company’s stock valued at $8,115,000 after purchasing an additional 12,121 shares during the period. Metis Global Partners LLC boosted its position in shares of Bristol-Myers Squibb by 14.8% in the 3rd quarter. Metis Global Partners LLC now owns 101,772 shares of the biopharmaceutical company’s stock valued at $5,907,000 after purchasing an additional 13,122 shares during the period. Jmac Enterprises LLC boosted its position in shares of Bristol-Myers Squibb by 11.4% in the 3rd quarter. Jmac Enterprises LLC now owns 12,171 shares of the biopharmaceutical company’s stock valued at $706,000 after purchasing an additional 1,245 shares during the period. Finally, Signaturefd LLC boosted its position in shares of Bristol-Myers Squibb by 0.5% in the 3rd quarter. Signaturefd LLC now owns 105,986 shares of the biopharmaceutical company’s stock valued at $6,151,000 after purchasing an additional 564 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Price Performance

BMY stock traded up $0.61 during trading on Friday, hitting $48.91. The company had a trading volume of 6,938,170 shares, compared to its average volume of 15,660,710. The company has a fifty day moving average price of $51.25 and a two-hundred day moving average price of $51.57. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24. The company has a market cap of $99.13 billion, a P/E ratio of 12.56, a P/E/G ratio of 1.44 and a beta of 0.39. Bristol-Myers Squibb has a fifty-two week low of $47.58 and a fifty-two week high of $70.93.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $1.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.55 by $0.15. Bristol-Myers Squibb had a return on equity of 50.95% and a net margin of 17.83%. The firm had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the previous year, the company posted $1.82 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. Equities research analysts expect that Bristol-Myers Squibb will post 6.63 earnings per share for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 1st. Shareholders of record on Friday, April 5th will be given a $0.60 dividend. The ex-dividend date of this dividend is Thursday, April 4th. This represents a $2.40 annualized dividend and a yield of 4.91%. Bristol-Myers Squibb’s payout ratio is 62.18%.

Analyst Upgrades and Downgrades

BMY has been the subject of several research analyst reports. Wells Fargo & Company increased their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an “equal weight” rating in a research note on Thursday. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Societe Generale downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. Redburn Atlantic downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Finally, Bank of America downgraded Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and cut their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $61.18.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.